Keyan Salari, MD, PhD
Keyan Salari, MD, PhD
Director, Prostate Cancer Genetics Program
Boston, MAPhone: 617-724-4000
Boston, MAPhone: 857-238-3838
About Keyan Salari, MD, PhD
Keyan Salari, MD, PhD is a urologic oncologist at the Massachusetts General Hospital and Harvard Medical School. He is a urologic surgeon specialized in the treatment of genitourinary cancers using open, laparoscopic, and robotic surgery techniques. His research focuses on applying cancer genomics and computational biology methods to advance precision cancer medicine for genitourinary malignancies.
Dr. Salari is a faculty member of the Department of Urology and a Urologic Oncologist at the Massachusetts General Hospital Cancer Center. He graduated with honors from the University of California at Berkeley with a B.A. in molecular and cellular biology, where he was awarded the Spencer W. Brown Award and was a Howard Hughes Medical Institute Biology Fellow. He earned his MD and PhD in Genetics from Stanford University School of Medicine in the NIH Medical Scientist Training Program. He trained in General Surgery and Urology at the Massachusetts General Hospital and subsequently completed a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center.
Dr. Salari’s clinical practice focuses on the surgical treatment of urologic cancers with a particular emphasis on prostate cancer, kidney cancer, and testicular cancer. He serves as Director of the Prostate Cancer Genetics Program, where families that may have a hereditary predisposition to prostate cancer are offered genetic testing, cancer screening, and support. His research interests focus on leveraging a variety of genomic technologies and computational biology methods to gain insight into the pathobiology of prostate cancer, with the goal of improving early detection of clinically significant prostate cancer and distinguishing indolent from aggressive disease to guide treatment decisions.
Departments, Centers, & Programs:
- Bladder cancer
- Cancer genetics
- Laparoscopic surgery, Robotic surgery, Open surgery
- Minimally invasive surgery
- Penile cancer
- Prostate cancer
- Renal Cancer
- Testicular cancer
- Ureteral Cancer
- Urethral Cancer
Mass General Cancer Center: Center for Genitourinary Cancers
55 Fruit St.
Boston, MA 02114
Mass General Urology
165 Cambridge St.
Boston, MA 02114
- MD, Stanford University
- Residency, Massachusetts General Hospital*****
- Fellowship, Memorial Sloan Kettering Cancer Center
American Board Certifications
- Urology, American Board of Urology
Accepted Insurance Plans
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- Mass General Brigham Health Plan - ACD
- Mass General Brigham Health Plan - PBO
- Medicare - ACD
- Medicare ACO - ACD
- Medicare ACO - PBO
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- He MX, Cuoco MS, Crowdis J, et al. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med. 2021 Mar;27(3):426-433. Epub 2021 Mar 4.
- AlDubayan SH, Conway JR, Camp SY, et al. Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma. JAMA. 2020 Nov 17;324(19):1957-1969. doi: 10.1001/jama.2020.20457.
- Liu D, Shoag J, Poliak D, et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun. 2020 Apr 24;11(1):1987.
- Hanna N, Wszolek MF, Mojtahed A, et al. Multiparametric MRI/ultrasound fusion biopsy improves but does not replace standard template biopsy for the detection of prostate cancer. J Urol. 2019 May 30.
- Salari K, Kuppermann D, Preston MA, et al. Active Surveillance of Prostate Cancer is a Viable Option in Men Younger Than 60 Years. J Urol. 2019 Apr;201(4):721-727.
- Wang Z, Hu L, Salari K, et al. Androgenic to Estrogenic Switch in Human Adult Prostate Gland as a result of Epigenetic Silencing of Steroid 5-α Reductase 2. J Pathol. 2017 Dec;243(4):457-467.
- Cuff J, Salari K, Esheba GE, et al. Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis. PLoS ONE 2013 Sep 9;8(9):e74562.
- Salari K, Spulak ME, Cuff J, et al. CDX2 is an amplified lineage-survival oncogene in colorectal cancer. Proc Natl Acad Sci USA. 2012 Nov 13;109(46):E3196-205.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
#1 Research Hospital in America
Mass General is the #1 hospital in New England based U.S. News & World Report Best Hospitals for 2022-2023.
Reviews: Comments and Ratings